(Q47746290)

5 February 2018

title

Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. (English)

1 reference

5 February 2018

0 references

1 reference

Alan S Brody

1

1 reference

5 February 2018

Heidi Sucharew

2

1 reference

5 February 2018

Jonathan D Campbell

3

1 reference

5 February 2018

Steven P Millard

4

1 reference

5 February 2018

Paul L Molina

5

1 reference

5 February 2018

Jeffrey S Klein

6

1 reference

5 February 2018

Joanne Quan

7

1 reference

5 February 2018

language of work or name

English

0 references

publication date

11 August 2005

1 reference

5 February 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

5 February 2018

volume

172

1 reference

5 February 2018

issue

9

1 reference

5 February 2018

page(s)

1128-1132

1 reference

5 February 2018

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Pulmonary function between 6 and 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Early morphologic changes in the lungs of asymptomatic infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Structural airway abnormalities in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

An automated approach to quantitative air trapping measurements in mild cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Lessons learned from recent cardiovascular clinical trials: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Biomarkers in imaging: realizing radiology's future

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200407-989OC

10.1164/RCCM.200407-989OC

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

16100015

1 reference

5 February 2018